Fluorinated cannabidiol derivatives: Enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Breuer, Aviva ^a   Haj, Christeene G ^a   Fogaça, Manoela V ^b   Gomes, Felipe V ^b   Silva, Nicole Rodrigues ^b   Pedrazzi, João Francisco ^b   Bel, Elaine A Del ^b   Hallak, Jaime C ^b   Crippa, José A ^b   Zuardi, Antonio W ^b   Mechoulam, Raphael ^a   Guimarães, Francisco S ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

10 FLUOROCANNABIDIOL DIACETATE; 4' FLUOROCANNABIDIOL; 8,9 DIHYDRO 7 FLUOROCANNABIDIOL DIACETATE; CANNABIDIOL DERIVATIVE; HU 577; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CANNABIDIOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; ARTICLE; CHROMATOGRAPHY; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG PURIFICATION; DRUG SYNTHESIS; DRUG TOLERABILITY; ELEVATED PLUS MAZE TEST; FLUORINATION; FORCED SWIM TEST; LIPOPHILICITY; MOUSE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PREPULSE INHIBITION; SCHIZOPHRENIA; TRANQUILIZING ACTIVITY; ANIMAL; ANIMAL BEHAVIOR; ANXIETY; ANXIETY DISORDERS; DEPRESSIVE DISORDER; DISEASE MODEL; DRUG EFFECTS; MALE; MOTOR ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY; ANXIETY DISORDERS; BEHAVIOR, ANIMAL; CANNABIDIOL; DEPRESSION; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; MALE; MICE; MOTOR ACTIVITY; SCHIZOPHRENIA;

EID: 84978636526     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0158779     Document Type: Article

References (52)

1. Adams R, Hunt M, Clark JH. Structure of cannabidiol, a product isolated from the marijuana extract of Minnesota wild hemp. J Am Chem Soc. 1940, 62; 196-200.
2. Jacob A, Todd AR. Cannabis indica. Part II. Isolation of cannabidiol from Egyptian hashish. Observations on the structure of cannabinol. J Chem Soc. 1940; 649-653.
3. Mechoulam R, Shvo Y. The structure of cannabidiol. Tetrahedron. 1963, 19; 2073-2078. PMID: 5879214
4. Mechoulam R, Gaoni Y. The absolute configuration of Δ1 -tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett. 1967; 1109-1111. PMID: 6039537
5. Mechoulam R, Parker LA, Gallily R. Cannabidiol: An overview of some pharmacological aspects. J Clin Pharmacol. 2002, 42; 11S-19S. PMID: 12412831
6. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol-recent advances. Chem Biodivers. 2007, 4; 1678-1692.
7. Zhornitsky S, Potvin S. Cannabidiol in humans-The quest for therapeutic targets. Pharmaceuticals (Basel). 2012, 5; 529-552.
8. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimaraes FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Phil Trans R Soc Lond B Biol Sci. 2012, 367; 3364-3378.
9. Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?. Br J Clin Pharmacol. 2013, 75; 323-333. doi: 10.1111/j.1365-2125.2012.04341.x PMID: 22625422
10. Renard J, Loureiro M, Rosen LG, Zunder J, de Oliveira C, Schmid S, et al. Cannabidiol counteracts amphetamine-induced neuronal and behavioral sensitization of the mesolimbic dopamine pathway through a novel mTOR/p70S6 kinase signaling pathway. J Neurosci. 2016, 4; 5160-9.
11. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel G, Gagliardi R, et al. Chronic administration of CBD to healthy volunteers and epileptic patients. Pharmacology. 1980, 21; 175-185. PMID: 7413719
12. Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. Seizure. 2016, 35; 41-44. doi: 10.1016/j.seizure.2016.01.004 PMID: 26800377
13. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016, 15; 270-278. doi: 10. 1016/S1474-4422(15)00379-8 PMID: 26724101
14. Detynecki K, Hirsch LT. Cannabidiol for epilepsy:trying to see through the haze. Lancet Neurol. 2016, 15; 270-278.
15. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl). 1982, 76; 245-50.
16. Zuardi AW, Rodrigues JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl). 1991, 104; 260-264.
17. Moreira FA, Guimaraes FS. Cannabidiol inhibits hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol. 2005, 512; 199-205. PMID: 15840405
18. Gomes FV, Issy AC, Ferreira FR, Viveros MP, Del Bel EA, Guimarães FS. Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice. Int J Neuropsychopharmacol. 2014, 18; 1-10.
19. Pedrazzi JF, Issy AC, Gomes FV, Guimarães FS, Del-Bel EA. Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine. Psychopharmacology (Berl). 2015, 232; 3057-3765.
20. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015, 12; 825-836. doi: 10.1007/s13311-015-0387-1 PMID: 26341731
21. Guimaraes FS, De Aquiar JC, Mechoulam R, Breuer A. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. General Pharmacol. 1994, 25; 161-164.
22. Campos AC, Ortega Z, Palazuelos J, Fogaça MV, Aguiar DC, Díaz-Alonso J, et al. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacol. 2013, 16; 1407-1419. doi: 10.1017/ S1461145712001502 PMID: 23298518
23. Bergamaschi MM, Queiroz RH, Chagas MH, De Oliveira DC, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011, 36; 1219-1226. doi: 10.1038/npp.2011.6 PMID: 21307846
24. Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SR. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol. 2010, 159; 122-128. doi: 10.1111/ j.1476-5381.2009.00521.x PMID: 20002102
25. Casarotto PC, Gomes FV, Resstel LB, Guimarães FS. Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors. Behav Pharmacol. 2010, 21; 353-8. PMID: 20695034
26. Zuardi AW, Morais SL, Guimarães FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry. 1995, 56; 485-6. PMID: 7559378
27. Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE, et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol. 2006, 20; 683-686. PMID: 16401651
28. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psych. 2012, 2; 1-7.
29. Meuth SG, Vila C, Dechant KL. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis. Expert Rev Neurother. 2015, 15; 909-918. doi: 10.1586/14737175.2015.1067607 PMID: 26166264
30. Begue JP, Bonnet-Delpont D. Bioorganic and Medicinal Chemistry of Fluorine; John Wiley & Sons, Inc., Hoboken: NJ, USA; 2008.
31. Muller K, Fach C, Diedrich F. Fluorine in pharmaceuticals:looking beyond intuition. Science. 2007, 317; 1881-1886. PMID: 17901324
32. Gaoni Y, Mechoulam R. The isolation and structure of Δ1 -THC and other neutral cannabinoids from hashish. J Am Chem Soc. 1971, 93; 217-224. PMID: 5538858
33. Kozela E, Haj C, Hanuš L, Chourasia M, Shurki A, Juknat A, et al. HU-446 and HU-465, derivatives of the non-psychoactive cannabinoid cannabidiol, decrease the activation of encephalitogenic T cells. Chem Biol Drug Des. 2016, 87; 143-153. doi: 10.1111/cbdd.12637 PMID: 26259697
34. Gomes FV, Casarotto PC, Resstel LB, Guimaraes FS. Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35; 434-8. doi: 10.1016/j.pnpbp.2010.11.027 PMID: 21111767
35. Bisogno T, Ortar G, Petrosino S, Morera E, Palazzo E, Nalli M, et al. Endocannabinoid Research Group. Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. Biochim Biophys Acta. 2009, 1791; 53-60.
36. File SE. Behavioural detection of anxiolytic action. In Experimental Approaches to Anxiety and Depression; Elliott JM, Heal DJ, Marsden CA, Editors. Chichester: Wiley; 1992. p. 25-44.
37. Njung'e K, Handley SL. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav. 1991, 38; 63-7. PMID: 2017455
38. Umemoto T, Fukami S, Tomizawa G, Harasawa K, Kawada K, Tomita K. Power- and structure-variable fluorinating agents. The N-fluoropyridinium salt system. J Am Chem Soc. 1990, 112; 8563-8575.
39. Jorapur VS, Duffley RP, Razdan RK. A procedure for the conversion of cannabidiol into 12β-Substituted tetrahydrocannabinols (THC's): Synthesis of 12β-Hydroxy-Δ9 -THC. Synth Commun. 1984, 14; 655-660.
40. Boukerb A, Gree D, Laabassi M, Gree R. Substituent effects on the regioselectivity in fluorination of allylic alcohols with DAST. J Fluor Chem. 1998, 88; 23-27.
41. Handley SL, Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn Schmiedebergs Arch Pharmacol. 1984, 327; 1-5. PMID: 6149466
42. Campos AC, Fogaça MV, Aguiar DC, Guimarães FS. Animal models of anxiety disorders and stress. Rev Bras Psiquiatr. 2013, 35; S101-S111. doi: 10.1590/1516-4446-2013-1139 PMID: 24271222
43. Guimarães FS, Chiaretti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl). 1990, 100; 558-559.
44. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav. 2005, 81; 331-342. PMID: 15927244
45. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci. 2002, 23; 238-245. PMID: 12008002
46. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977, 266; 730-732. PMID: 559941
47. Linge R, Jiménez-Sánchez L, Campa L, Pilar-Cuéllar F, Vidal R, Pazos A, et al. Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: Role of 5-HT1A receptors. Neuropharmacology. 2016, 103; 16-26. doi: 10.1016/j.neuropharm.2015.12.017 PMID: 26711860
48. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl). 2001, 156; 117-154.
49. Swerdlow NR, Braff DL, Geyer MA. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav Pharmacol. 2000, 11; 185-204. PMID: 11103873
50. Long LE, Malone DT, Taylor DA. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacol. 2006, 31; 795-803.
51. Thomas A, Burant A, Bui N, Graham D, Yuva-Paylor LA, Paylor R. Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology (Berl) 2009, 204; 361-373
52. Stern CA, Gazarini L, Takahashi RN, Guimarães FS, Bertoglio LJ. On disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment. Neuropsychopharmacol. 2012, 37; 2132-42.